Subscribe
Share
Share
Embed
Board Pearls is a gastroenterology board review built around clinical reasoning, not recall. Each episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards.
The gastroenterology series covers the full blueprint across nine modules: esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics. Episodes are grouped by chapter and built from the primary guidelines and pivotal trials the boards draw from (ACG, AGA, AASLD, ASGE), not from textbook summaries.
Use it as an audio companion to the written curriculum, MCQs, and AI tutor at boardpearls.com. Questions or feedback: hello@boardpearls.com.
Welcome to Board Pearls. This is episode three of three of the Barrett Esophagus and Esophageal Cancer chapter, in the Esophageal Disorders module. In this episode we cover esophageal cancer staging and treatment: the histology split between adenocarcinoma and squamous cell carcinoma, TNM staging with the T1a-versus-T1b boundary as the endoscopic-eligible line, and the CROSS neoadjuvant regimen and the FLOT perioperative regimen for locally advanced adenocarcinoma.
The cancer side picks up where eradication ends, with the patient whose visible lesion turns out on EMR to have invaded past the mucosa, or who presents with cancer outside a known Barrett field.
Esophageal cancer divides into two histologies that share a tube but live different lives. Adenocarcinoma is the dominant US histology and has tripled to sextupled in incidence over the past three decades. It sits in the distal third and at the gastroesophageal junction, and it is biologically driven by GERD, central obesity, smoking, and Barrett. Squamous cell carcinoma is the dominant histology worldwide at around ninety percent of cases. It has declined in US incidence and sits in the mid-thoracic esophagus. The drivers are tobacco, alcohol, hot beverages, achalasia, lye stricture, tylosis, lichen planus, and human papillomavirus in some populations. The histology should be the first thing the candidate sorts in a vignette, because it predicts the risk-factor stem, the anatomic location, and the treatment intensity. A mid-thoracic tumor in a heavy smoker with achalasia is squamous until biopsy proves otherwise. A distal tumor in a man with chronic reflux and central obesity is adenocarcinoma.
A few risk-factor associations are worth holding by name. Tylosis is the autosomal dominant palmoplantar keratoderma caused by germline RHBDF2 mutations. Despite the dermatology label it is a squamous cell carcinoma syndrome, with a lifetime esophageal SCC risk approaching ninety-five percent by age sixty-five. Lye ingestion produces decades-later squamous cell carcinoma in the area of the chronic stricture, and surveillance starting around fifteen to twenty years after the injury is reasonable. Achalasia carries a roughly point-seven to three-point-three percent lifetime SCC risk, but routine surveillance is not supported because the absolute risk does not reach the threshold the surveillance literature demands. Hot beverages above sixty-five degrees Celsius are classified by the WHO as a probable carcinogen for esophageal squamous cell carcinoma. The candidate who sees a vignette pairing very hot tea with a mid-esophageal mass should not need to look up the association.
TNM staging is the engine that selects the treatment lane, and the T categories carry the boards points the candidate must hold cold. Tis is high-grade dysplasia. The columnar tract no longer uses carcinoma in situ. T1 invades the lamina propria, the muscularis mucosae, or the submucosa, and it splits at the muscularis mucosae. T1a stays at or above the muscularis mucosae. T1b crosses into the submucosa. T2 invades the muscularis propria. T3 invades the adventitia. T4a invades adjacent structures that a surgeon can take with the specimen, meaning pleura, pericardium, or diaphragm. T4b invades structures the surgeon cannot resect, meaning aorta, vertebral body, or trachea. The nodal count is N1 for one to two regional nodes, N2 for three to six, N3 for seven or more. M0 is no distant metastasis, M1 includes distant nodes and distant organ metastasis.
The reason the T1a versus T1b line matters more than any other staging boundary in this disease is the lymph node metastasis risk that maps onto depth of invasion. T1a is subdivided into m1, m2, and m3. The m1 lesion is intramucosal carcinoma confined to the epithelium. The m2 lesion invades the lamina propria but spares the muscularis mucosae. The m3 lesion invades but does not penetrate the muscularis mucosae. Nodal risk is under two percent for m1 and m2 and four to seven percent for m3. T1b is subdivided into sm1, sm2, and sm3 by depth into the submucosa, with sm1 under five hundred micrometers, and the nodal risk climbs with each step. Nodal risk for sm1 is roughly thirteen percent, for sm2 around twenty-six percent, and for sm3 up to sixty-seven percent. That jump at the muscularis mucosae is the reason T1a is endoscopic in essentially all cases and T1b crosses the surgical threshold for most.
The exception that the boards reward is the favorable T1b sm1 patient who can still be managed endoscopically. The qualifiers are specific. Invasion under five hundred micrometers, well or moderately differentiated histology, no lymphovascular invasion, no perineural invasion, R0 lateral and deep margins on en-bloc resection. The patient also has to have a reason to avoid surgery, usually significant comorbidity. The framework is that even in favorable T1b sm1 the nodal risk is around five to ten percent. The patient and the surgeon weigh that against the perioperative mortality of esophagectomy at high-volume centers, around two to five percent, plus the morbidity. The AGA Clinical Practice Update supports continued endoscopic management with intensive surveillance in that specific subgroup, and the boards expect the candidate to recognize it as an option rather than to default to mandatory esophagectomy. Sm2 and sm3 belong to surgery.
T2 node-negative disease is generally surgical, with the role of neoadjuvant therapy in T2N0 debated. The board-ready answer is that upfront esophagectomy and neoadjuvant chemoradiation followed by esophagectomy are both reasonable options in T2N0, and the choice turns on tumor and patient features. Locally advanced disease, which means T3, T4a, or any node-positive M0 disease, is treated with neoadjuvant chemoradiation followed by esophagectomy in adenocarcinoma and in the majority of resectable squamous cell carcinoma. M1 disease is palliative.
The staging package follows a fixed order, and the order is mechanistic rather than memorized. EGD with biopsies establishes the diagnosis and the histology. EMR or ESD of any visible early lesion provides the gold-standard T-stage for T1 disease, because forceps biopsies cannot determine depth of invasion. CT of the chest and abdomen with contrast assesses gross local extent, regional adenopathy, and distant metastasis. PET-CT identifies distant metastatic disease and changes M staging in candidates for curative-intent therapy. Endoscopic ultrasound provides the most accurate locoregional T and N staging, with fine-needle aspiration of suspicious nodes that adds a tissue diagnosis and can change the stage. The order to remember is EGD, then CT, then PET, then EUS, and EMR or ESD whenever a visible lesion might be T1.
Esophagectomy in modern practice carries volume-dependent operative mortality of roughly two to ten percent and morbidity around thirty to forty percent. The complications include anastomotic leak, anastomotic stricture, chylothorax, atrial fibrillation, pneumonia, and the long-term sequelae of dumping, diarrhea, and reflux. Average length of stay at high-volume centers is seven to ten days. Two main approaches dominate. The Ivor Lewis transthoracic approach is favored for distal adenocarcinoma. The McKeown three-field approach and the transhiatal approach are selected based on tumor location and surgeon preference. Outcomes are better at high-volume centers, and referral to such a center is part of the right answer.
Two trials carry the systemic therapy lanes for resectable locally advanced disease, and the candidate has to hold both. The first is CROSS, the canonical neoadjuvant chemoradiation regimen. CROSS randomized three hundred sixty-six patients with T1 node-positive or T2 to T3 with any node status esophageal or gastroesophageal junction cancer to neoadjuvant chemoradiation followed by surgery versus surgery alone. The chemoradiation arm received weekly carboplatin dosed to an area-under-the-curve of two, plus weekly paclitaxel at fifty milligrams per square meter, for five weeks, combined with forty-one-point-four gray of concurrent radiation delivered in twenty-three fractions. The survival numbers are the ones to carry. Median overall survival improved from twenty-four months to forty-nine months. Five-year survival improved from thirty-three percent to forty-seven percent. The absolute benefit was larger in squamous cell carcinoma than in adenocarcinoma. Pathologic complete response was achieved in roughly twenty-nine percent overall, with a higher rate in squamous cell carcinoma. CROSS established carboplatin-paclitaxel plus forty-one-point-four gray as the neoadjuvant standard for resectable locally advanced esophageal cancer of both histologies.
The second is FLOT4, the perioperative chemotherapy alternative for resectable adenocarcinoma of the gastroesophageal junction and stomach. FLOT4 randomized seven hundred sixteen patients with cT2 or higher resectable gastric or gastroesophageal junction adenocarcinoma, or any node-positive disease, to perioperative FLOT versus the older ECF or ECX regimen. The FLOT schedule is four cycles before and four cycles after surgery. ECF and ECX were epirubicin, cisplatin, and fluorouracil or capecitabine. FLOT itself is fluorouracil at twenty-six hundred milligrams per square meter, leucovorin at two hundred milligrams per square meter, oxaliplatin at eighty-five milligrams per square meter, and docetaxel at fifty milligrams per square meter. The FLOT survival gain mirrors it. Median overall survival improved from thirty-five months to fifty months. Five-year survival improved from thirty-six percent to forty-five percent. FLOT is now the perioperative standard for adenocarcinoma of the gastroesophageal junction and stomach. The way to hold both trials is by histology and modality. CROSS is the neoadjuvant chemoradiation regimen for esophageal adenocarcinoma and squamous cell carcinoma. FLOT is the perioperative chemotherapy alternative for adenocarcinoma of the gastroesophageal junction and stomach when chemoradiation is not selected.
CheckMate 577 added an adjuvant immunotherapy lane to the post-CROSS post-resection setting. Patients with residual disease in the resection specimen after neoadjuvant chemoradiation and esophagectomy, meaning any T or N other than ypT0N0, were randomized to nivolumab versus placebo for up to one year. Nivolumab roughly doubled disease-free survival, from eleven months to twenty-two months. The translation for the boards is recognition. Any patient with residual disease at esophagectomy after CROSS-style neoadjuvant therapy is a candidate for one year of adjuvant nivolumab.
Definitive chemoradiation is the curative-intent answer in squamous cell carcinoma patients who are not surgical candidates and is preferred over surgery for cervical and very proximal squamous cell carcinoma where the surgical anatomy is unfavorable. A cervical squamous cell carcinoma vignette with a tumor sitting above the thoracic inlet is not a CROSS-then-esophagectomy case. It is a definitive chemoradiation case, because esophagectomy in that location requires a total laryngectomy and the functional cost is unacceptable when chemoradiation gives comparable oncologic outcomes. Five-year survival with definitive chemoradiation is around twenty-five percent in squamous cell carcinoma and around twenty percent in adenocarcinoma. The dose for definitive non-surgical chemoradiation is typically fifty-point-four gray in twenty-eight fractions with concurrent cisplatin and fluorouracil or carboplatin and paclitaxel.
Palliation in M1 disease is built around symptom control and systemic therapy. Self-expandable metal stents relieve dysphagia in luminally obstructing disease and are the workhorse for malignant dysphagia. External-beam radiation is an option when stenting fails or is not tolerated. Systemic therapy in metastatic adenocarcinoma is platinum and fluoropyrimidine doublets with the addition of nivolumab or pembrolizumab in PD-L1 expressing tumors and trastuzumab in HER2-positive tumors. That biomarker testing matters enough that HER2 immunohistochemistry with reflex fluorescence in situ hybridization for two-plus immunohistochemistry is standard at diagnosis of metastatic gastroesophageal junction adenocarcinoma, because trastuzumab adds survival in the HER2-positive subset. Metastatic squamous cell carcinoma is treated with platinum and fluoropyrimidine doublets plus pembrolizumab or nivolumab, with first-line randomized trial data supporting checkpoint inhibition. Five-year survival in metastatic esophageal cancer remains under five percent regardless of histology.
A few smaller points sit on the boundary of the cancer chapter and adjacent material. Anastomotic stricture occurs in ten to thirty percent of esophagectomies and responds to balloon dilation in most cases. Chronic reflux after esophagectomy is common because the operation destroys the antireflux barrier, and lifelong PPI is standard. Scleroderma esophagus, with absent peristalsis and a hypotensive lower esophageal sphincter, drives severe reflux and is associated with Barrett in five to thirty-five percent of patients, but adenocarcinoma in that population is rare.
The arc this episode has been tracing is the arc that the patient travels from a visible nodule to an answer. The nodule is resected before the field is ablated, because the resection is the staging test. The pathology either keeps the patient endoscopic, by confirming intramucosal disease or favorable T1b sm1, or sends the patient to surgery, by confirming sm2 or sm3 invasion or any node-positive locally advanced disease. The patient who lands in the locally advanced lane gets neoadjuvant chemoradiation by CROSS or perioperative chemotherapy by FLOT depending on histology and tumor location. The patient with residual disease after CROSS gets one year of adjuvant nivolumab. The patient with metastatic disease gets palliation, with biomarker-directed systemic therapy added for HER2 and PD-L1 positive tumors. Throughout, the staging package runs in a fixed order, EGD then CT then PET then EUS, with EMR or ESD as the gold-standard T-stage for any visible T1 lesion.
The next chapter shifts the lens entirely. Eosinophilic esophagitis is a T-helper-two allergic disease defined histologically by fifteen eosinophils per high-power field, with a therapeutic ladder of proton pump inhibitors, swallowed topical steroids, and dietary elimination. Sitting alongside it are the infectious esophagitides, where Candida, herpes simplex virus, and cytomegalovirus sort by host immune status and by where the organism lives in the wall, which is what dictates the biopsy site.